
Biodesix (BDSX) Stock Forecast & Price Target
Biodesix (BDSX) Analyst Ratings
Bulls say
Biodesix is well-positioned for future growth, with a strong revenue stream from both its core lung disease testing and its expanding biopharma services segment. Its proprietary multi-omic AI platform and differentiated suite of liquid biopsy tests, combined with a large and underpenetrated addressable market, provide significant potential for long-term expansion. While there are risks including market competition and the need for continued revenue growth and potential additional capital, the company's experienced leadership and track record of product launches instill confidence in its ability to succeed.
Bears say
Biodesix is showing promising signs of improving financials with a narrowed net loss and improved cash burn, but the company's relatively thin cash position and continued reliance on equity issuance pose a significant risk. The company's revenue is also dependent on reimbursement decisions, and any changes to Medicare coverage could significantly impact earnings. Additionally, the company's future profitability hinges on reaching cash flow break-even, which may not be achieved before further dilution erodes potential upside.
This aggregate rating is based on analysts' research of Biodesix and is not a guaranteed prediction by Public.com or investment advice.
Biodesix (BDSX) Analyst Forecast & Price Prediction
Start investing in Biodesix (BDSX)
Order type
Buy in
Order amount
Est. shares
0 shares